These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 8347333)
1. A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Bierer LM; Aisen PS; Davidson M; Ryan TM; Stern RG; Schmeidler J; Davis KL Alzheimer Dis Assoc Disord; 1993; 7(2):98-104. PubMed ID: 8347333 [TBL] [Abstract][Full Text] [Related]
2. A pilot study of clonidine plus physostigmine in Alzheimer's disease. Bierer LM; Aisen PS; Davidson M; Ryan TM; Schmeidler J; Davis KL Dementia; 1994; 5(5):243-6. PubMed ID: 7951680 [TBL] [Abstract][Full Text] [Related]
3. Oral physostigmine treatment of patients with Alzheimer's disease. Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. Möller H-J ; Hampel H; Hegerl U; Schmitt W; Walter K Pharmacopsychiatry; 1999 May; 32(3):99-106. PubMed ID: 10463377 [TBL] [Abstract][Full Text] [Related]
5. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study. Davidson M; Bierer LM; Kaminsky R; Ryan TM; Davis KL Alzheimer Dis Assoc Disord; 1989; 3(4):224-7. PubMed ID: 2688700 [TBL] [Abstract][Full Text] [Related]
6. Long-term administration of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398 [TBL] [Abstract][Full Text] [Related]
7. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl. Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668 [TBL] [Abstract][Full Text] [Related]
8. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial. Jenike MA; Albert M; Baer L; Gunther J J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429 [TBL] [Abstract][Full Text] [Related]
9. Effects of oral physostigmine in Alzheimer's disease. Stern Y; Sano M; Mayeux R Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795 [TBL] [Abstract][Full Text] [Related]
10. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group. van Dyck CH; Newhouse P; Falk WE; Mattes JA Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658 [TBL] [Abstract][Full Text] [Related]
12. L-deprenyl and physostigmine for the treatment of Alzheimer's disease. Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774 [TBL] [Abstract][Full Text] [Related]
14. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. Jenike MA; Albert MS; Heller H; Gunther J; Goff D J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997 [TBL] [Abstract][Full Text] [Related]
15. Transdermal physostigmine in the treatment of Alzheimer's disease. Levy A; Brandeis R; Treves TA; Meshulam Y; Mawassi F; Feiler D; Wengier A; Glikfeld P; Grunwald J; Dachir S Alzheimer Dis Assoc Disord; 1994; 8(1):15-21. PubMed ID: 8185877 [TBL] [Abstract][Full Text] [Related]
16. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. Imbimbo BP; Troetel WM; Martelli P; Lucchelli F Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357 [TBL] [Abstract][Full Text] [Related]
17. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease. Schneider LS; Olin JT; Pawluczyk S Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085 [TBL] [Abstract][Full Text] [Related]
18. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group. Canal N; Imbimbo BP Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240 [TBL] [Abstract][Full Text] [Related]
19. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Peskind ER; Wingerson D; Pascualy M; Thal L; Veith RC; Dorsa DM; Bodenheimer S; Raskind MA Biol Psychiatry; 1995 Oct; 38(8):532-8. PubMed ID: 8562665 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Beller SA; Overall JE; Swann AC Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]